Matching articles for "Merilog"
In Brief: Merilog — A NovoLog Biosimilar
The Medical Letter on Drugs and Therapeutics • June 23, 2025; (Issue 1731)
The FDA has approved Merilog (Sanofi), a biosimilar to
rapid-acting insulin aspart (NovoLog), for treatment of
patients with type 1 or type 2 diabetes. Merilog is the
first rapid-acting insulin biosimilar...
The FDA has approved Merilog (Sanofi), a biosimilar to
rapid-acting insulin aspart (NovoLog), for treatment of
patients with type 1 or type 2 diabetes. Merilog is the
first rapid-acting insulin biosimilar product to become
available in the US.